Recently, the Type 1 Diabetes Genetics Consortium (T1DGC) reported 22 novel type 1 diabetes (T1D)-associated loci identified by meta-analysis of three genome-wide association studies (GWASs) with a case -control design. However, the association of 10 of these 22 reported loci was not confirmed in the T1DGC family cohort (P > 0.1). To address concerns about potential bias from population stratification, this study aims to replicate the association in three independent GWAS cohorts, one of which was based on the stratificationproof transmission disequilibrium analysis. Three European-descent population samples were included in this study: 483 cases and both parents, a case-control cohort of 514 cases and 2027 controls, and an additional cohort of 1078 cases and 341 controls from the dbGaP database. Among the 22 SNPs reported by the T1DGC, we had high-quality genotypes for 15; the remaining were imputed. T1D association was replicated in seven loci after Bonferroni correction for 22 independent hypotheses. An additional eight loci had nominal (onesided) significance of P < 0.1 in the same direction, giving a false discovery rate of 3.35%. The genetic susceptibility conferred by non-HLA loci in our family cohort with one affected offspring was higher than the T1DGC multiplex families. Reciprocally, the frequency of strongly predisposing HLA alleles in the multiplex families was higher. This study replicated T1D association with at least as many of these novel loci as expected from the power of our sample size, thus supporting the validity of the new discoveries.
INTRODUCTION
Type 1 diabetes (T1D) is caused by T-cell-mediated autoimmune destruction of the pancreatic b-cells, in which genetic predisposition has an important role. The risk to siblings of type 1 diabetic individuals is about 15 times that of general population (1) and the concordance rate for monozygotic twins is much higher than that for dizygotic twins (2) . A number of T1D loci have been identified by the candidategene approach and genome-wide association studies (GWASs) (3 -7) . Most recently, the Type 1 Diabetes Genetics Consortium (T1DGC) reported 22 novel T1D associated loci identified by the meta analysis of the T1DGC GWAS data and two previous GWAS studies with case -control design, with additional evidence from one case -control cohort and one family cohort (8) . However, the association of 10 of these 22 reported loci was not replicated in the T1DGC family cohort (single tail a ¼ 0.1), although this family cohort had .80% statistical power to replicate each locus (8) .
As T1D has a dramatic difference in the prevalence rates among different populations, the discrepancy between findings in the case -control and family-based data might raise concerns of population-stratification artifacts that may not have been corrected sufficiently in case -control studies. Therefore, it was important to validate these loci in independent populations. The purpose of this study was to examine the new loci in GWAS data from our two independent European cohorts (5, 9) , with the addition of the only other publicly available independent European cohort that was not included in the original meta analysis (8) for a total of 1550 cases and 2238 controls in addition to 483 case -parent trios.
RESULTS
Among the 22 T1D-associated single-nucleotide polymorphisms (SNPs) reported by the T1DGC, 15 SNPs genotyped on our and the DCCT/EDIC HumanHap550 array had high genotyping call rates, the lowest being 99.4%. Mendelian error was seen in only one family for a single SNP. Three of the 15 SNPs were not genotyped on the controls of the IBD study, which were imputed based on the HumanHap300 genotyping data. Of the remaining 7 imputed SNPs, rs12444268 at Chr16p12.3 was poorly tagged by the surrounding SNPs with low imputation certainty (Table 1) . T1D association of seven loci was replicated in our three cohorts with P , 4.55 × 10
23
, while an additional eight loci had a nominal significance of 4.55 × 10 23 , P , 0.1. The T1D association of seven loci was not replicated ( Table 1 ). Four of these seven unreplicated loci had no significance in the T1DGC family cohort, either.
As shown by the T1DGC report (8) , the association in the families tends to have a smaller effect than that of the casecontrol cohort, which may not entirely be explained by winner's curse. To assess the potential bias of false positives from population stratification, a quantile -quantile (Q -Q) plot (10) was produced by combining two family cohorts, i.e. our family cohort and the T1DGC family cohort (Fig. 1) . By this immune to population stratification approach, we can see compelling evidence of T1D association. Among the 15 loci, 7 most significant loci with P ≤ 3.97 × 10 23 were replicated for T1D association. The FDR of the 15 loci with P , 0.1 was 3.35% (11), indicating that most or all of them represent true associations. This may still be an underestimate. The affected siblings in the multiplex families of the T1DGC data set may have higher frequency of high-risk HLA genotypes that would reduce the effect sizes of other T1D loci compared with sporadic T1D cases (8) . Indeed, the aggregate frequency of HLA-DQB1 * 0201/0302 plus DQB1 * 0201/0201 plus DQB1 * 0302/0302, the three most predisposing genotypes, was significantly higher (P ¼ 3.6 × 10 26 ) in the multiplex set (61.0%) than in the trios (51.2%).
We then compared the effect sizes of four known T1D loci between 2298 T1DGC families with affected siblings (5003 affected siblings, the T1DGC rapid response data) and 900 Canadian families with one affected offspring. As shown in Table 2 , the effect sizes of four independent SNPs at the four loci are smaller in the T1DGC cohort, without exception (P ¼ 0.008 by the t-test of logarithms of relative risks). The difference of the PTPN22 SNP rs2476601 was significant on its own, with P ¼ 0.028, concordant with a previous report (12) .
DISCUSSION
Our study replicated at least as many of the T1DGC loci as would be expected from the statistical power of our sample sizes, as shown in Figure 2 . The comparisons of the statistical powers of each cohort of this study are shown in Supplementary Material, Figure S1 . As shown by 100 000 iterations of simulation, the statistical power of this study allows the replication of 12 of the reported association loci at a ¼ 0. Fig. S2 ). This provides an independent support for the validity of all or most reported loci. A possible exception is an unreplicated locus, rs7804356, at Chr7p15.2, which may be due to an overestimate of effect size in the T1DGC case-control cohort. In spite of the high significance in the T1DGC case -control cohort, no association was detected in the T1DGC families. The OR of rs7804356 went to the opposite direction in the family cohort of our study. Statistically significant heterogeneity (P ¼ 0.012) was shown by comparing the effect of the T1DGC case-control cohort versus the combined effect, OR (95% confidence interval) ¼ 1.00 (0.93, 1.06), of the T1DGC family cohort and our family cohort.
This study validated the T1D association of several novel loci reported by the T1DGC. Further investigation of the functional mechanisms of these loci in the T1D pathogenesis will promote the knowledge of the disease, albeit more disease loci with minor effect sizes remain to be identified (13) . We cannot estimate the timeline that all the genetic susceptibility of T1D will be explained. However, the finding of each novel locus is important. The clarification of the novel loci will offer more opportunities for the cure of the disease.
MATERIALS AND METHODS

Subjects
The Children's Hospital of Philadelphia (CHOP)-Montreal cohorts. Two samples of European populations of this study, i.e. one family cohort and one case -control cohort, were described in our previous reports (5,9). The casecontrol cohort consisted of 514 T1D cases and 2027 controls. The family cohort included 483 complete T1D case -parent trios. The median age of the T1D patients was 8 with lower and upper quartiles at 4.6 years and 11 years. The Research Ethics Board of the Montreal Children's Hospital, the Research Ethics Board of the Children's Hospital of Philadelphia and other participating centers approved the study, and written informed consent was obtained from all subjects.
The DCCT/EDIC cases (14) and the controls used in the IBD study. This cohort includes 1078 T1D cases and 341 controls with European ancestry [Supplementary Material, Fig. S3  (15) ]. Ethnic outliers were identified by principal components analysis (PCA), and were not included in this study. The GWAS data of this cohort were acquired from the National Center for Biotechnology Information Genotypes and Phenotypes Database (NCBI dbGaP, http://www.ncbi.nlm. nih.gov/gap).
Genotyping
All DNA samples of the CHOP-Montreal cohorts were genotyped for 550 000 SNPs on the Illumina HumanHap550 array (Illumina, San Diego, CA, USA). The DCCT/EDIC cases were genotyped for 550 000 SNPs on the Illumina HumanHap550 array. The controls of the IBD study were genotyped for 317 503 SNPs on the Illumina HumanHap300 array. Among the 22 SNP markers with T1D association reported by the (17) . For the imputed SNPs, the association was tested using imputed dosage data by the mach2dat software (http://www.sph.umich.edu/csg/abecasis/mach/download). The joint analysis of the three cohorts was done by combining the ORs (95% confidence interval) using the Comprehensive Meta Analysis software (www.Meta-Analysis.com). The effects in this replication study should have the same direction as reported. As 22 SNPs were tested for T1D association, the corrected significant level is 4.55 × 10 23 , i.e. the single tail significance 0.1 divided by 22 comparisons. Figure 1 . The quantile-quantile (Q-Q) plot produced by the combined P-values of two family cohorts, i.e. our family cohort and the T1DGC family cohort. This approach is immune to population stratification; therefore, the dramatic deviation from the null expectation suggests compelling evidence of T1D association of this group of novel loci. Figure 2 . The statistical power of this study to detect genetic associations of each T1DGC locus at a ¼ 0.1 and a ¼ 4.55 × 10 23 , respectively. The effect size of each locus was estimated by the joint analysis of the T1DGC casecontrol cohort and the T1DGC family cohort.
